Journals / The Anatolian Journal of Cardiology / 2015 / Cilt: 15 - Sayı: 7

Highlights from ACC 15 Scientific Sessions: Part 2

Pages
596–600
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
🔖

Cite This Article

KAYMAZ, C., TOKGÖZOĞLU, L. (2015). Highlights from ACC 15 Scientific Sessions: Part 2. The Anatolian Journal of Cardiology, Cilt: 15 - Sayı: 7, 596–600. https://ajindex.com/articles/365578

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Gillinov AM, Gelijns AC, Parides MK, DeRose JJ Jr, Moskowitz AJ, Voisine P, et al. Surgical ablation of atrial fibrillation during mitral- valve surgery. N Engl J Med 2015; 372: 1399-409. [CrossRef] 2. DiBiase D. Ablation vs. Amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: Results from the AATAC Multicenter Randomized Trial. Presented at: American College of Cardiology/i2 Scientific Session; March 16, 2015;
  2. San Diego, CA. 3. Mega JL, Walker JR, Ruff CT, Vandell AG, Nordio F, Murphy SA, et al. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 2015: pii: S0140-6736(14)61994-2. 4. Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX, et al. Long-Term Effect of Goal Directed Weight Management in an Atrial Fibrillation Cohort: A Long-term Follow-Up StudY (LEGACY Study). J Am Coll Cardiol 2015; 65: 2159-69. [CrossRef] 5. Hausenloy DJ. Effect of remote ischemic preconditioning on clini- cal outcomes in patients undergoing coronary artery bypass graft surgery: a multi-center randomized controlled clinical trial. Presented at: American College of Cardiology/i2 Scientific Session; March 16, 2015;
  3. San Diego, CA. 6. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al.; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evo- locumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9. [CrossRef] 7. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al; ODYSSEY LONG TERM Investigators Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99. [CrossRef] 8. Stone NJ, Lloyd-Jones DM. Lowering LDL cholesterol is good, but how and in whom? N Engl J Med 2015; 372: 1564-5. [CrossRef] 9. Reddy M, Atoui M, Pillarisetti J, Gunda S, Atkins D, Bommana S, et al. Externalization of Conductor Cables in QuickSite and QuickFlex Left Ventricular Leads. ACC 15 Moderated Poster presentation No 1129M-03, March 14, 2015
  4. San Diego, CA. 10. Maron BJ, Rowin EJ, Casey S, Link M, Lesser JR, Chan RHM, et al. Paradigm Change in the Demographics of Mortality in Hypertrophic Cardiomyopathy. ACC 15 Moderated Poster presentation no 1269M-07, March 16, 2015
  5. San Diego, CA. 11. Svatikova A, Covassin N, Somers K, Soucek F, Kara T, Ruzek L, et al. Potenti